Physician profile
Michael Park
NPI 1942204680
$6,553.58
in general payments reported to CMS, 2019-2025
30 companies · $1,145 in 2025
The $1,145 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $645 · 2021: $1,051 · 2022: $982 · 2023: $1,201 · 2024: $855 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,124.08 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,396.73 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,248.30 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $463.27 | 2019-2025 | |
| Grifols USA, LLC | $398.71 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Amgen INC. | $372.62 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $325.94 | 2021-2025 | Xolair |
| Glaxosmithkline, LLC. | $313.91 | 2019-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $253.98 | 2019-2024 | |
| Kaleo, INC. | $216.82 | 2019-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $206.78 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.69 | 2019-2023 | Spiriva Respimat |
| Csl Behring | $129.98 | 2019-2025 | Hizentra, Haegarda |
| Regeneron Healthcare Solutions, INC. | $127.47 | 2019-2025 | Dupixent |
| Abbott Laboratories | $124.81 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $116.12 | 2025 | Neffy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $89.82 | 2021-2023 | Cuvitru, Hyqvia |
| Aimmune Therapeutics, INC. | $85.83 | 2020-2022 | |
| Pfizer INC. | $85.39 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $76.99 | 2025 | |
| Covis Pharma Gmbh | $62.28 | 2021 | |
| Verona Pharma, INC. | $53.54 | 2025 | Ohtuvayre |
| Incyte Corporation | $52.98 | 2021-2023 | Opzelura |
| Alk-Abello, INC | $41.44 | 2019-2025 | Standardized Mite D. Farinae, Alternaria Tenuis, Timothy, Standardized |
| Merck Sharp & Dohme LLC | $33.87 | 2021-2023 | |
| Lundbeck LLC | $22.19 | 2021 | |
| Lilly USA, LLC | $21.98 | 2025 | Ebglyss |
| Cycle Pharmaceuticals INC | $18.85 | 2025 | Sajazir |
| Paratek Pharmaceuticals, INC. | $17.26 | 2025 | Xhance |
| Invivyd INC | $17.22 | 2025 | Pemgarda |
| Abbvie INC. | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.